C. Michael White, PharmD
Philadelphia—Withdrawing aspirin therapy and continuing ticagrelor monotherapy three months after percutaneous coronary intervention (PCI) in patients with non–ST-segment elevation acute coronary syndrome (ACS) lowers bleeding risk without raising ischemic risk, according to new data presented at the American Heart Association’s 2019 Scientific Sessions.
The data are from a substudy of TWILIGHT-ACS that included 4,614 patients from TWILIGHT